Purpose Embolization is mainly used to reduce the size of locally advanced tumors. In this study, selective arterial catheterization with chitosan micro-hydrogels (CMH) into the femoral artery was performed and the therapeutic effect was validated using different imaging methods. Methods Male SD rats (n=18, 6 weeks old) were randomly assigned into three groups: Group 1 as control, Group 2 without any ligation of distal femoral artery, and Group 3 with temporary ligation of the distal femoral artery. RR1022 sarcoma cell lines were inoculated into thigh muscle. After 1week, CMH was injected into the proximal femoral artery. Different imaging modalities were performed during a 3-week followup. Results The tumor size was significantly (P < 0.001) decreased in both Group 2 and Group 3 (P<0.001) after selective arterial embolization therapy. 
Introduction
The main goal of tumor treatment is to remove tumors or to reduce subsidiarily the growth of tumor size. Radical therapy such as a surgical operation is one of the main approaches to remove tumors [1] . Although surgical operation helps remove a tumor from the body, it usually needs long admission with complications [2] . Neoadjuvant therapy, a pre-treatment before therapeutic agents are administrated to reduce tumor growth, makes further procedures of treatment easier and likely to succeed [3] . Various therapeutic techniques including immunotherapy, hormone therapy, chemotherapy, radiation therapy, and embolization therapy are commonly used as neoadjuvant therapy in clinical circumstances [4] [5] [6] . Embolization therapy is especially often used to reduce growth of locally advanced tumors in ischemic change induced by occlusion of blood vessels. Compared with other approaches, embolization therapy has several advantages, including minimal invasions, no scars, rare risk of infection, and high success rate of treatment with minimal complication [7] . One of the representative approach of e m b o l i z a t i o n t h e r a p y i s t r a n s c a t h e t e r a r t e r i a l chemoembolization (TACE) on hepatocellular carcinoma (HCC). TACE has been used to treat cancer or to reduce the size of tumor in HCC by administration of anticancer drug and lipiodol, one of the embolic agents, into the selected hepatic artery in the liver before main treatment such as brachytherapy [8] . The embolic agents include liquid embolic agents (n-butyl-2-cyanoacrylate and ethiodol), sclerosing agents (ethanol, ethanolamine oleate, sotradecol), mechanical occlusion devices (coils, detachable balloon), and particulate embolic agents (gelfoam hemostasis, polyvinyl alcohol, acrylic gelatin microspheres) [9] . Chitosan, a natural carbohydrate polymer modified by partial N-deacetylation of chitin, is commonly used in biomedical fields recently due to its biological safety, non-toxicity, biocompatibility, biodegradability, and easy preparation method [10] . We have established a synthetic method for the preparation of chitosan micro-hydrogel (CMH) that is uniform and stable. In this study, we tried to use these particles as an embolic agent. The purpose of this study was to evaluate the efficacy of selective arterial embolization therapy for cancer treatment using molecular imaging modality to trace the infused molecules and to evaluate cancer metabolism. To validate the therapeutic effect of the embolic agents, ultrasonography was used to measure the diameter size, and also gamma camera and positron emission tomography with computed tomography (PET/CT) using 18 F-fluorodeoxyglucose ( 18 F-FDG) were utilized [11] [12] [13] [14] [15] .
Materials and Methods

Materials
Chitosan (molecular weight, 300 kDa; deacetylation, 98 %) was purchased from Youngchipharm (Paju, Korea). Sulfosuccinimidyl-3-(-4hydroxypheynyl) propionate (SHPP) was bought from Thermo Fisher (Waltham, MA, USA). Sodium triphosphate pentabasic (TPP) and boric acid were obtained from Sigma-Aldrich (St. Louis, MO, USA). Poly-mesh was purchased from TEXTOMA (Daegu, Korea). Isoflurane was obtained from Hana Pharmaceutical (Hwasung, Korea). Na 125 I was obtained from Perkin Elmer Life Science (Boston, MA, USA). Surgical sutures were purchased from ETHICON (Somerville, NJ, USA). Human serum and Cyclosporin A were provided by Chonbuk National University Hospital (Jeonju, Korea).
Synthesis of Chitosan-SHPP Chitosan (1,000 mg) was dissolved in HCl (0.1 N, 100 mL) at 4°C for 5 h followed by the addition of borate buffer (pH 7.3, 200 mL). Sulfo SHPP (10 mg) diluted in DMSO (0.2 mL) was added into chitosan solution and reacted under N 2 purge for 15 h at −4°C. This chitosan-SHPP solution was dialyzed for 3 days and then lyophilized for 1 week. The morphology of CMH was identified by optical microscope (DP72; OLYM-PUS, Shinjuku, Tokyo, Japan). 
Animal
All animal experiments were performed in compliance with policy and procedure of the Institutional Animal Care and Use Committee in Chonbuk National University of South Korea. Male Sprague-Dawley rats (n=18, 6 weeks old) were purchased from Orient-Bio (Seoul, Korea). Rats were randomly assigned into three groups: Group 1 as control, Group 2 without any ligation of femoral artery, and Group 3 with permanent ligation at the distal part which faces down from inoculation site in femoral artery.
Preparation of Rat Models Inoculated With Sarcoma Cells
During experiment days, all rats were treated with the immunosuppressant cyclosporin A (CsA, 20 mg/kg) at -1, 0, +1, +2, +4 days of inoculation of the RR1022 sarcoma cell lines. Before surgery for inoculation, rats were anesthetized with isoflurane (2 %) through inhalation. Surgery started with a small incision in the proximal site of the right thigh. The RR1022 sarcoma cells (1×10 7 /rat), combined with normal saline, were inoculated into the space between the femoral muscle and fascia near the femoral artery using insulin syringes (31-gauge). After the inoculation, the small incision was sutured using 3-0 surgical black silk.
One week after the inoculation, in Group 2, CMH (300 μL) was injected into the proximal femoral artery via intravenous catheter (24-gauge); in Group 3, the distal site of the femoral artery was ligated by 3-0 surgical black silk and 125 I-labeled CMH (300 μL) was injected into the proximal femoral artery. The injection site punctured by catheterization was repaired with a small piece of polyethylene catheter tube.
Assessment of Tumor Status Using Imaging Modalities
All rats during imaging acquisition were anesthetized with isoflurane (2 %). After 1 week of tumor inoculation, 18 F-FDG (18 MBq) was injected into all rats through tail vein injection. Rats were lied down at prone position on the bed. 18 F-FDG PET/CT images were acquired for 30 min to identify glucose metabolic status of tumor by using the Animal PET/CT system (FLEX Pre-clinical Platform; Gamma Medica-Ideas, Salem, USA) at the 1st and the 3rd week. Volume of interest (VOI) for tumor was drawn by visualized three-dimensional analysis software from Life Science (Amira; FEI, MA, USA). To estimate the intensity of I were detected by a gamma camera and presented to planar imaging. Photographic images of body (prone position) were also obtained to verify the location where 125 I-labeled CMH was in the body. In Groups 2 and 3, photographic images were taken during experiments to verify hindlimb ischemia induced by CMH.
Assessment of Hematoxylin and Eosin (H & E) Stain
To analyze histology of femoral muscle and tumor mass, all rats were euthanized in a N 2 chamber for subsequent histological analysis. Axial sections sampled across the center of the tumor were fixed in 10 % buffered formaldehyde solution and paraffin embedded. H & E staining of every section was performed. After tumor removal for H & E staining, each rat was euthanized in a nitric oxide (NO) chamber.
Statistical Analysis
All data sets were calculated and represented as mean±SD. Statistical differences between three groups were analyzed by one-way analysis of variance (ANOVA) followed by post-hoc tests for multiple comparisons (Group 1 versus Group 2, Group 1 versus Group 3 and Group 2 versus Group 3) on SPSS 12.0 statistics software (SPSS, Chicago, IL, USA). Statistically significant difference was considered when the P value was less than 0.05.
Results
Characterization of 125 I-Labeled Chitosan Micro-Hydrogels (CMH)
The conceptual diagram for the preparation of 125 I-CMH is described in Fig. 1 to understand the experimental procedure. The size of CMH was between 100 and 150 μm as measured under an optical microscope (Fig. 2) . CMH had smooth surfaces and spherical shapes. The efficiency of CMH measured for around 140 min in Fig. 5 Glucose metabolic activity of tumor in each group. The yellowcolored circle indicates a tumor as expected. The red-colored ellipse in the 3rd week of Group 2 indicates an inflammatory cellular uptake induced by ischemia due to CMH distribution into arterial system of right hindlimb normal saline solution was over 90 %, suggesting that the labeling condition between CMH and 125 I was highly stable (Fig. 3) .
Assessment of Imaging Modalities
From the results of the ultrasonography, we calculated the change of tumor size at follow-up time point. Tumor size change as well as tumor development were easily monitored with difference in echogenicity (Fig. 4) . Transverse images of the right thigh represented heterogeneous and decreased echogenicity in the region of the tumors in Groups 2 and 3 with time.
18 F-FDG-PET/CT imaging revealed that the glucose metabolic uptake of tumors had higher intensity than other normal sites (Fig. 5) 125 I planar images using gamma camera revealed that 125 I-CMH was distributed all over the right hindlimb in Group 2 and accumulated near the tumor as expected in Group 3 (Fig. 6 ).
Pathologic Findings
In visual photographic imaging, serial change of the right limb was observed in Group 2, suggesting hindlimb ischemia induced by CMH which became worse during follow-ups. However, no significant change was detected in Group 3 (Fig. 7) . H & E stains showed that tumor cells in Group 1 were intact without dominant inflammatory infiltration or tumor necrosis. In contrast, tumor cells in Group 2 were pyknotic with inflammatory infiltration. In Group 3, there were significant ischemic necrosis and inflammatory infiltration (Fig. 8) .
Analysis of Tumor Volume Changes
In the result of Group 1, the tumor volume (V 1w = 1.54 cm 3 , V 2w =6.47 cm 3 , V 3w =5.73 cm 3 ) was highly increased initially and then slightly decreased for 3 weeks. However, in Group 2 (V 1w =1.32 cm 3 , V 2w = 2.71 cm 3 , V 3w =1.16 cm 3 ) and Group 3 (V 1w =1.44 cm 3 , V 2w = 2.84 cm 3 , V 3w = 0.91 cm 3 ), the tumor volumes were very slowly increased initially and then decreased to the small size at the beginning of follow-up periods (Fig. 9 ). 
Discussion
We used selective arterial embolization to reduce tumor growths to reveal that our CMH would be useful as an embolic agent. We also used molecular imaging to evaluate the procedure and tumor status. Embolization of peripheral tumor using CMH showed successful diminishment of tumor size and metabolism. Appropriate utilization of molecular imaging modalities informed us of the proper approach for therapeutic substances to target lesion and predict therapeutic effect or complications. In this study, it was important to know whether adequate part of artery was ligated before the administration of CMH. Results from Group 2 showed an excellent effect of reducing tumor size as from Group 3. However, hindlimb ischemia was induced because the descending part of the femoral artery was not ligated, so that CMH flowed into the arterial system of lower limb over all. On the other hand, the administrated CMH accumulated in the arteries of Group 3, providing blood supplies to the tumor which induced the embolization effect because the descending part of femoral artery was ligated to guide CMH into the branched artery heading to the tumor.
To prepare rat models with sarcoma, we inoculated the RR1022 sarcoma cells into the space between the thigh muscle and fascia near the femoral artery and selected superficial femoral artery for easy access and lower complication [16] . So, the proximal and superficial femoral artery was catheterized by 24-gauge needle of IV catheters during the selective arterial catheterization. In Group 3, we raised the probability that injected CMH was guided more into the artery heading to the tumor by occluding the distal part of the superficial femoral artery selected by catheterization.
A number of imaging modalities in radiology and nuclear medicine can provide anatomical and functional information through the whole body to diagnose pathological interpretation in pre-clinical and clinical circumstances. A radiopharmaceutical such as 18 F-FDG offers functional information on the glycolic metabolism of a tumor to verify tumor status with quantitative information as well as localization. We assessed the change of 18 F-FDG uptake as similar to the change of tumor volume. Thus, tumor status could be verified by comparing the change of 18 F-FDG uptake and tumor size. In addition, the reason that Group 3 showed lower 18 F-FDG uptake than Group 2 is assumed to be because the tumor necrosis induced by the embolization effect of CMH into tumor in Group 3 had progressed more than in Group 2. Ultrasonography has been well known to provide anatomical information to diagnose diseases or tumor in real time. The tumor size was easily measured by ultrasound during experiments. Even though the operator needs to be skilled at handling the ultrasound device, ultrasonography is very helpful to diagnose several targets. Accordingly, nuclear medicine and radiology based imaging technique could be useful with pre-clinical and clinical follow-ups [17] .
Specific iodine radioisotopes have been commonly used to diagnose or treat diseases of clinical importance. 125 I used in the current study is most commonly used to produce radiolabeled compounds for in vitro experiments. 125 I has very low gamma energy (27-35 keV) of photons, which preclinical gamma camera can acquire in vivo study image. Radioisotope 131 I has been used to irradiate mainly cancer cells therapeutically. 131 I also emits gamma and beta emission simultaneously. This characteristic permits this radioisotope to be used in the theranostics field as well [18, 19] . Therefore, if CMH labeled with radioisotope 131 I instead of 125 I is used, more highly effective selective arterial radioembolization as main treatment is expected in future studies.
Conclusion
Selective arterial embolization therapy with CMH was significantly effective for tumor treatment in a rodent sarcoma model involving implantation in thigh muscle. Molecular imaging modalities including ultrasonography are feasible to be utilized as anatomical imaging tools to provide valuable information on the location and amount of embolic agent and glycolic metabolism of a tumor. The information will help researchers predict the possibilities of therapeutic success, complication development, and tumor metabolic status. Fig. 9 The tumor size in Group 2 and 3 was changed significantly compared with Group 1. The groups treated by embolization showed greater inhibition rate in tumor growth. *P<0.05, **P<0.001
